{"id":"NCT01908829","sponsor":"Astellas Pharma Europe Ltd.","briefTitle":"A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)","officialTitle":"A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-07-10","primaryCompletion":"2014-11-24","completion":"2014-11-25","firstPosted":"2013-07-26","resultsPosted":"2017-10-09","lastUpdate":"2024-10-31"},"enrollment":2174,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Urinary Bladder Diseases","Urinary Bladder Overactive","Urologic Diseases"],"interventions":[{"type":"DRUG","name":"mirabegron 25 mg","otherNames":["Betmiga","Myrbetriq","YM178","Betanis"]},{"type":"DRUG","name":"mirabegron 50 mg","otherNames":["YM905","Vesitrim","Vesikur","Vesicare"]},{"type":"DRUG","name":"solifenacin 5 mg","otherNames":["Vesicare","Vesitrim","YM905","Vesikur"]},{"type":"DRUG","name":"solifenacin 10 mg","otherNames":["Vesicare","Vesitrim","YM905","Vesikur"]},{"type":"DRUG","name":"mirabegron 25 mg matching placebo","otherNames":[]},{"type":"DRUG","name":"mirabegron 50 mg matching placebo","otherNames":[]},{"type":"DRUG","name":"solifenacin 5 mg matching placebo","otherNames":[]},{"type":"DRUG","name":"solifenacin 10 mg matching placebo","otherNames":[]}],"arms":[{"label":"Combination (solifenacin + mirabegron)","type":"EXPERIMENTAL"},{"label":"Solifenacin 5 mg","type":"ACTIVE_COMPARATOR"},{"label":"Solifenacin 10 mg","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to see if adding a new type of medication recently approved to treat overactive bladder (mirabegron) to an antimuscarinic treatment (solifenacin) would be more effective in controlling incontinence than when using the antimuscarinic treatment alone.","primaryOutcome":{"measure":"Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours","timeFrame":"Baseline and end of treatment (up to 12 weeks)","effectByArm":[{"arm":"Combination (Solifenacin + Mirabegron)","deltaMin":-1.8,"sd":0.08},{"arm":"Solifenacin 5 mg","deltaMin":-1.53,"sd":0.08},{"arm":"Solifenacin 10 mg","deltaMin":-1.67,"sd":0.08}],"pValues":[{"comp":"OG000 vs OG001","p":"=0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":219,"countries":["United States","Armenia","Australia","Austria","Belgium","Canada","Czechia","Denmark","Finland","France","Georgia","Germany","Greece","Hungary","Ireland","Israel","Italy","Lebanon","Netherlands","Norway","Poland","Portugal","Romania","Russia","Slovakia","Slovenia","Spain","Sweden","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["28916436","26965560"],"seeAlso":["https://astellasclinicalstudyresults.com/study.aspx?ID=247"]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":725},"commonTop":["Dry mouth"]}}